Dr. Paul Richardson on the Phase 2b STORM Study

Triple-class refractory multiple myeloma (TCR-MM) is defined as being refractory to immunomodulatory agents, proteasome inhibitors, and anti-CD38 mAbs, representing an urgent unmet medical need with a median overall survival (OS) of 3-5 months(Pick M et al, Eur J Haem 2018; Gandhi U et al, ASH 2018). Xpovio (selinixor) and dexamethasone (Xd) has shown a 26.2% overall response rate (ORR) in 122 patients (pts) with TCR-MM in the Phase 2b STORM study (Chari A et al, ASH 2018). Here, we evaluate the OS of patients in the STORM study with Xpovio (selinixor) and dexamethasone (Xd) and in patients with bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab (“penta”)-exposed, TCR-MM from an observational cohort not receiving Xd.

Conclusions:

The prognosis of TCR-MM in the real-world population appears very poor. Within the limits of this analysis, median OS of pts receiving Xd as their first therapy after their MM becomes TCR is significantly better than those not receiving Xd, suggesting that Xd may be associated with an OS benefit in patients with TCR-MM. 

Authors:

Paul G. Richardson, Sundar Jagannath, Ajai Chari, Dan T. Vogl, Meletios A. Dimopoulos, Philippe Moreau, David Dingli, L J Wei, Lingling Li, Shijie Tang, William Reichman, Michael G. Kauffman, Jatin J. Shah, Sharon Shacham, Sagar Lonial; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Mount Sinai Medical Center, New York, NY; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; Abramson Cancer Center, Philadelphia, PA; National and Kapodistrian University of Athens, Athens, Greece; CHU de Nantes-Hôtel Dieu, Nantes, France; Mayo Clinic, Rochester, MN; Harvard School of Public Health, Boston, MA; Karyopharm Therapeutics, Newton, MA; Karyopharm Therapeutics Inc, Newton, MA; Karyopharm Therapeutics Inc., Newton, MA; Winship Cancer Institute of Emory University, Atlanta, GA

Clinical trial information: NCT02336815

ASCO 2019 Abstract No: 8014

Citation: 
J Clin Oncol 37, 2019 (suppl; abstr 8014)

ABOUT PAUL RICHARDSON, MD

Paul Richardson, M.D. is the Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston. He is also an Institute Physician and a RJ Corman Professor of Medicine, at Harvard Medical School in Cambridge, MA. In addition to multiple myeloma, his key clinical interests are regimen-related toxicity, stem cell transplantation, experimental therapies and cancer pharmacology, and more. Visit Dr. Paul Richardson’s full biography.